Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations

Asian Pacific Journal of Allergy and Immunology

Volumn 27, Issue 4, 2009, Pages 233-236

  Chularojanamontri, Leena ^a   Wimoolchart, Saranjit ^a   Tuchinda, Papapit ^a   Kulthanan, Kanokvalai ^a   Kiewjoy, Nisa ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; OMALIZUMAB; STEROID; TACROLIMUS; MONOCLONAL ANTIBODY;

ADULT; ALOPECIA; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; ECZEMA; FEMALE; HUMAN; HYPER IGE SYNDROME; HYPEREOSINOPHILIA; LABORATORY DIAGNOSIS; LYMPHOCYTIC INFILTRATION; NAIL DYSTROPHY; NATURAL KILLER CELL; PHYSICAL EXAMINATION; SKIN BIOPSY; SKIN CANDIDIASIS; SKIN DEFECT; SKIN DISEASE; SKIN PRURITUS; BLOOD; CANDIDA; DRUG EFFECT; EOSINOPHILIA; ERYTHEMA; IMMUNOLOGY; LYMPHOCYTOSIS; ONYCHOMYCOSIS; PATHOGENICITY; PATHOLOGY; PATHOPHYSIOLOGY; PRURITUS; SKIN; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTIBODIES, MONOCLONAL; CANDIDA; DIAGNOSIS, DIFFERENTIAL; EOSINOPHILIA; ERYTHEMA; FEMALE; HUMANS; IMMUNOGLOBULIN E; INJECTIONS, SUBCUTANEOUS; JOB'S SYNDROME; LYMPHOCYTOSIS; ONYCHOMYCOSIS; PRURITUS; SKIN;

EID: 77953626683     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Grimbacher B, Schaffer AA, Holland SM, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 1999; 65: 735-44.
2. Al Khatib S, Keles S, Garcia-Lloret M, et al. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome. J Allergy Clin Immunol 2009; 124: 342-8.
3. Minegishi Y, Karasuyama H. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: les-sons from a primary immunodeficiency. Int Immunol 2009; 21: 105-12.
4. Grimbacher B, Holland SM, Puck JM. Hyper-IgE syndromes. Immunol Rev 2005; 203: 244-50.
5. Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections- an autosomal dominant multisystem disorder. N Engl J Med 1999; 340: 692-702.
6. Moin M, Farhoudi A, Movahedi M, et al. The clinical and laboratory survey of Iranian patients with hyper-IgE syndrome. Scand J Infect Dis 2006; 38: 898-903.
7. Bard S, Paravisini A, Aviles-Izquierdo JA, Fernandez-Cruz E, Sanchez-Ramon S. Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizu-mab. Arch Dermatol 2008; 144: 1662-3.
8. Pherwani AV, Madnani NA. Hyperimmunoglobulin E syndrome. Indian Pediatr 2001; 38: 1029-34.
9. Yamazaki-Nakashimada M, Zaltzman-Girshevich S, Garcia de la Puente S, et al. Hyper-IgE syndrome and autoimmuni-ty in Mexican children. Pediatr Nephrol 2006; 21: 1200-5.
10. North J, Kotecha S, Houtman P, Whaley K. Systemic lupus erythematosus complicating hyper IgE syndrome. Br J Rheumatol 1997; 36: 297-8.
11. Eberting CL, Davis J, Puck JM, Holland SM, Turner ML. Dermatitis and the newborn rash of hyper-IgE syndrome. Arch Dermatol 2004; 140: 1119-25.
12. Lee MW, Choi JH, Sung KJ, Moon KC, Koh JK. Extensive xanthelasma associated with anaplastic large cell lymphoma and hyperimmunoglobulin E syndrome. Int J Dermatol 2003; 42: 944-6.
13. Erbagci Z. Childhood bullous pemphigoid in association with hyperimmunoglobulin E syndrome. Pediatr Dermatol 2008; 25: 28-33.
14. Menni S, Croci S, Crupi A, Saleh F. Gingival hyperplasia and hyper IgE syndrome. Dent Cadmos 1990; 58: 76-9.
15. Clark TJ, Herod JJ, Kehoe S, Luesley DM. The development of invasive vulvar cancer in a patient with Job's syndrome, a rare immunodeficient condition. Br J Obstet Gynaecol 1998; 105: 468-70.
16. Ohameje NU, Loveless JW, Saini SS. Atopic dermatitis or hyper-IgE syndrome? Allergy Asthma Proc 2006; 27: 289-91.
17. Kerns MJ, Graves JE, Smith DI, Heffernan MP. Off-label uses of biologic agents in dermatology: a 2006 update. Se-min Cutan Med Surg 2006; 25: 226-40.
18. Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol 2007; 56: e55-79.
19. Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007; 120: 1223-5.
20. Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006; 117: 1493-9.